Related Experiment Video
Updated: Jun 9, 2026

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
Published on: February 14, 2012
Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle
Anwar Norazit1, Adrian C B Meedeniya, Maria Nga Nguyen
1National Centre for Adult Stem Cell Research, Eskitis Institute, Griffith University, Brisbane, Queensland, Australia.
Abstract:
Rotenone, a mitochondrial complex 1 inhibitor, causes oxidative damage via production of reactive oxygen species. We examined the pathophysiology of neuronal and glial cells of the nigrostriatal pathway following unilateral infusion of varying doses of rotenone into the substantia nigra or medial forebrain bundle of adult male Sprague-Dawley rats, sacrificed 14 and 60 days after infusion. Immunofluorescence techniques were used to qualitatively and quantitatively assay dopaminergic neurons, their projections, glial cells, synapses, and oxidative stress. Rotenone infusion into the substantia nigra at all concentrations caused extensive damage and tissue necrosis, therefore of limited relevance for producing a Parkinson disease model. Infusion of 0.5μg of rotenone targeting the medial forebrain bundle induced oxidative stress in dopaminergic neurons causing ongoing cell stress as defined by an elevation of stress granule and oxidative stress markers. This treatment resulted in the loss of tyrosine hydroxylase immunoreactive cells in the substantia nigra (p≤0.01) and loss of tyrosine hydroxylase immunoreactive nerve fibres and synaptic specialisations in the striatum (p≤0.01). The infusion of 0.5μg of rotenone also caused an increase in astrocytes and microglial cells in the substantia nigra in comparison to control (p≤0.01). We examined the time-dependent reduction of tyrosine hydroxylase-positive nerve fibres and cell bodies in the striatum and substantia nigra respectively, with a progressive reduction evident 60days after infusion (p≤0.01, p≤0.05). Dopaminergic axons exposed to low-dose rotenone undergo oxidative stress, with a resultant ongoing loss of dopaminergic neurons, providing an animal model relevant to Parkinson disease.
Insights
Low-dose rotenone infusion into the medial forebrain bundle induces oxidative stress and loss of dopaminergic neurons in rats. This provides a relevant animal model for Parkinson disease research.
Area of Science:
- Neuroscience
- Toxicology
- Pathophysiology
Background:
- Rotenone inhibits mitochondrial complex 1, leading to oxidative damage via reactive oxygen species.
- Understanding rotenone's effects on the nigrostriatal pathway is crucial for modeling neurodegenerative diseases.
Purpose of the Study:
- To investigate the pathophysiology of neuronal and glial cells in the nigrostriatal pathway after rotenone infusion.
- To establish a relevant animal model for Parkinson disease.
Main Methods:
- Unilateral infusion of varying rotenone doses into the substantia nigra or medial forebrain bundle of Sprague-Dawley rats.
- Immunofluorescence techniques to assess dopaminergic neurons, glial cells, synapses, and oxidative stress markers at 14 and 60 days post-infusion.
Main Results:
- Substantia nigra infusion caused extensive necrosis, limiting its use as a Parkinson disease model.
- Medial forebrain bundle infusion (0.5μg rotenone) induced oxidative stress and loss of dopaminergic neurons and striatal fibers.
- Increased astrocyte and microglial activation was observed in the substantia nigra.
Conclusions:
- Low-dose rotenone targeting the medial forebrain bundle causes oxidative stress and progressive dopaminergic neurodegeneration.
- This method provides a viable animal model for studying Parkinson disease pathophysiology and potential therapeutics.
Related Concept Videos
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis
Neural Regulation

